Insights from 2024 ATS Annual Meeting


 

ATS 2024 Insights: Interim Results From the Phase 1B and Phase 2 TORREY Open-Label Extension Study of Seralutinib in PAH

269 views
June 18, 2024
Comments 0
Login to view comments. Click here to Login